

REMARKS


At page two of the instant Office Action, the Examiner has required restriction among eight (8) groups of inventions, namely: a method of treating an individual afflicted with Alzheimer's disease comprising administering a compound which inhibits amyloid precursor protein iphosphorylation (Group I, claims 1-22, 33-44, and 46-56); a method of diagnosing Alzheimer's disease (Group II, claims 23-32); a compound for inhibiting cleavage of amyloid precursor protein (Group III, claim 45); a method of identifying a compound that inhibits Alzheimer's symptoms (Group IV, claims 57-72); a transgenic mouse (Group V, claims 73-84); a cell line established from a transgenic mouse (Group VI, claim 85); an assay for determining the effect of a compound on a feature of a neurodegenerative disorder comprising testing said compound on transgenic mice (Group VII, claims 86-93); and an assay for determining the effect of a compound on a feature of a neurodegenerative disorder comprising testing said compound on a transgenic cell line (Group VIII, claims 94-100).

Applicants respectfully traverse the restriction requirement. Applicants believe that the subject matter of claims 1-100 is interrelated to the extent that a search and examination of the subject matter of those claims in the same application would not be overburdensome.

Notwithstanding, Applicants elect the invention of Group V, claims 73-84 drawn to a transgenic mouse, for prosecution on the merits. Should the claims of Group V be found to be patentable, Applicants respectfully request that claim 85, Group VI, be rejoined.

Respectfully submitted,

Dated: April 21, 2006


John P. Iwanicki, Reg. No. 34,628
BANNER & WITCOFF, LTD.
28 State Street, 28th Floor
Boston, MA 02109
Phone: (617) 720-9600 s